What's in Charlotte Runge's pipeline?

Charlotte Runge has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Charlotte Runge's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/charlotte-runge.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Charlotte Runge — Portfolio Competitive Intelligence Brief

Charlotte Runge pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase
Popliteal Plexus Block with 20 ml	Popliteal Plexus Block with 20 ml	marketed
Popliteal Plexus Block with 10 ml	Popliteal Plexus Block with 10 ml	marketed
Popliteal Plexus Block with 30 ml	Popliteal Plexus Block with 30 ml	marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Charlotte Runge:

Cite this brief

Drug Landscape (2026). Charlotte Runge — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/charlotte-runge. Accessed 2026-05-16.